Search clinical trials for: Telaglenastat

Total 17 results

Washington University School of Medicine
National Cancer Institute (NCI); Calithera Biosciences, Inc

Not yet recruiting

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Cervical Cancer | Cervix Cancer | Advanced Cervical Carcinoma | Cancer of the Cervix

United States
Massachusetts General Hospital
Pfizer; Prostate Cancer Foundation; Calithera Biosciences, Inc

Not yet recruiting

Telaglenastat + Talazoparib In Prostate Cancer

Prostate Cancer Metastatic

United States
National Cancer Institute (NCI)

Recruiting

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Leptomeningeal Neoplasm | Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor

United States
National Cancer Institute (NCI)

Active, not recruiting

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2 | Astrocytoma, IDH-Mutant, Grade 3

United States
Calithera Biosciences, Inc

Completed

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma (CANTATA)

Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

United States, United Kingdom, Australia, France, Italy, Germany, Spain, New Zealand
Calithera Biosciences, Inc

Terminated

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Clear Cell Renal Cell Carcinoma (ccRCC)

United States
Calithera Biosciences, Inc

Terminated

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

Non-Small Cell Lung Cancer | Non-squamous Non-small-cell Lung Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | KEAP1 Gene Mutation | NFE2L2 Gene Mutation | NRF2 Mutation

United States
Calithera Biosciences, Inc

Completed

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer | TNBC - Triple-Negative Breast Cancer

United States
Calithera Biosciences, Inc

Terminated

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE)

Non-Small Cell Lung Cancer | Non-squamous Non-small-cell Lung Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | KEAP1 Gene Mutation | NRF2 Gene Mutation | NFE2L2 Gene Mutation

United States
Calithera Biosciences, Inc

Completed

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

NSCLC | Solid Tumors | KRAS Gene Mutation | CRC

United States
Calithera Biosciences, Inc

Completed

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) (ENTRATA)

Clear Cell Renal Cell Carcinoma

United States
Calithera Biosciences, Inc

Terminated

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Clear Cell Renal Cell Carcinoma | Colorectal Cancer | Solid Tumor | CRC | TNBC - Triple-Negative Breast Cancer | ccRCC | RCC

United States
Calithera Biosciences, Inc

Completed

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

Cardiac Safety

United Kingdom
Calithera Biosciences, Inc
Novotech (Australia) Pty Limited

Completed

Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects

Drug Interaction

Australia

Search clinical trials for: Telaglenastat

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations